Lilly announced interim data from the 800 patient, Phase II, BLAZE-1 trial (NCT04427501), where treatment with LY-CoV555 reduced viral load at day 11 with 2,800 mg, but not 700 mg or 7,000 mg compared to placebo in patients with mild to moderate COVID-19. A pooled analysis of all doses of LY-CoV555 found that 1.7% required hospitalization or an ER visit compared to 6% in the placebo group.
Merck initiated a 260 patient, Phase I/II trial (NCT04498247) to evaluate the safety, tolerability and immunogenicity of its COVID-19 vaccine, V591, in September 2020.
CanSino is evaluating a two-dose regimen of Ad5-nCoV in a 168 patient, Phase I trial (NCT04552366) in China.
Roche announced that in the 28-day, 389 patient, Phase III EMPACTA trial (NCT04372186), 12.2% of patients treated with tocilizumab progressed to mechanical ventilation or death compared to 19.3% of patients treated with placebo in hospitalized patients with COVID-19 who did not require noninvasive or invasive mechanical ventilation. Almost 85% of patients were non-white with the majority being Hispanic, with inclusion of Native American and Black populations.